Full-text preview

Available from: ncbi.nlm.nih.gov
Breast Carcinomas Arising at a Young
Age: Unique Biology or a Surrogate
for Aggressive Intrinsic Subtypes?
TO THE EDITOR: In the July 10, 2008 issue of Journal of Clinical
we reported a large-scale genomic analysis illustrating that
mRNA expression levels of key breast cancer-associated genes, ER-
, epithelial growth factor receptor (EGFR), and human epider-
mal growth factor receptor 2 (HER2) occurred in an age-related man-
ner. Moreover, when stratified by age, breast tumors arising in
younger women ( 45 years) were enriched with 350 biologically
relevant gene sets compared with those arising in older women ( 65
Breast cancer is no longer viewed as a single disease, but rather
a compilation of several distinct subtypes defined via gene expression
Microarray techniques have divided breast cancer into in-
trinsic subtypes: luminal A, luminal B, HER2-enriched, and basal-like,
each with unique prognostic and therapeutic implications.
On the
basis of findings from Carey et al,
we hypothesized that (1) breast
tumors arising in younger women may be more enriched for aggres-
sive subtypes and (2) age-specific biologic differences observed in
breast carcinomas may be highly subtype dependent. To evaluate the
relationship between age and breast cancer subtype, and to account for
potential confounding variables not previously included, we have
performed new analyses on data from Anders et al
and include a
similar analysis performed on a second independent microarray-
based breast tumor data set.
To explore our hypotheses, we chose to reanalyze our previous
data set; however, we limited our current analyses to a combination of
two of the four large data sets used previously, genomic spatial event
(GSE) 4922
and GSE7849,
termed data set A. Please note that two of
the four previous data sets were excluded (GSE2034
and GSE3143
because they lacked complete clinical data (ie, histologic grade). Our
first goal was to define the distribution of intrinsic subtypes assigned
by the PAM50
to determine whether subtype correlated with age
distinction. We hypothesized that more aggressive subtypes (ie, basal-
like) would be over-represented among breast carcinomas arising in
younger women ( 45 years), whereas older women ( 65 years)
would more commonly be diagnosed with luminal tumors.
As ex-
pected, there was a significant association between subtype and age
(P 3.8e-06; Table 1). Specifically, a higher proportion of younger
women were diagnosed with basal-like (odds ratio [OR], 12.27; 95%
CI, 3.96 to 45.0) and HER2-enriched (OR, 4.63; 95% CI, 1.50 to 16.48)
breast tumors.
Recognizing that age-specific differences in subtype distribu-
tion were present, we next examined other potential confounding
variables and noted that grade and sample source were associated
with age (Table 1). We hypothesized that accounting for all significant
Table 1. Age-Specific Clinical Characteristics of Data Set A (GSE4922 and GSE7849; age 45 and 65 years)
All (N 192)
( 45;
n 48)
( 65;
n 144)
Odds Ratio P 95% CINo. % No. % No. %
Estrogen receptor
Positive 156 83 38 81 118 84 1.28 .58 0.51 to 2.96
Negative 31 17 9 19 22 16 1.00 NA NA
Nodal status
Positive 57 31 17 35 40 30 0.77 .46 0.38 to 1.57
Negative 126 69 31 65 95 70 1.00 NA NA
Tumor size
2 cm 109 57 23 48 86 60 1.00 NA NA
2 cm 83 43 25 52 58 40 0.62 .16 0.32 to 1.20
Histologic grade
1 41 22 6 13 35 25 0.31 .015 0.10 to 0.80
2 82 44 16 36 66 47 0.43 .025 0.20 to 0.90
3 63 34 23 51 40 28 1.00 NA NA
Subtype (PAM50)
Lum A 51 27 5 13 46 38 1.00 NA NA
Lum B 46 24 5 13 41 34 1.12 .87 0.28 to 4.45
HER2 35 18 12 31 23 19 4.63 7.0e-03 1.50 to 16.48
Basal 29 15 17 44 12 10 12.27 5.2e-06 3.96 to 45.0
Normal 31 16 9 19 22 15 3.65 .033 1.11 to 13.50
GSE4922 156 81 33 69 123 85 1.00 NA NA
GSE7849 36 19 15 31 21 15 0.38 .015 0.17 to 0.83
Abbreviations: NA, not available; PAM, prediction analysis of microarray; Lum, luminal; HER2, human epidermal growth factor receptor 2; GSE, genomic spatial event.
e18 © 2010 by American Society of Clinical Oncology
Journal of Clinical Oncology, Vol 29, No 1 (January 1), 2011: pp e18-e20
Page 1

You are reading a preview. Would you like to access the full-text?

  • Source
    • "These results may indicate that young male BRCA2 mutation carriers could be susceptible to more aggressive (i.e., high-grade) breast cancer. Differences in grade among male breast carcinomas by age may be an indicator of a biologic complexity in MBC, as suggested in FBC [24]. In a previous, single-country case series, MBCs associated with BRCA2 mutations were found to be of higher grade than non-BRCA2 MBC [16] . "
    [Show abstract] [Hide abstract] ABSTRACT: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12). Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.
    Full-text · Article · Dec 2016 · Breast cancer research: BCR
  • Source
    • "Previous studies have suggested that YA-BC tumors exhibit clinical and pathological characteristics of a more aggressive disease, associated with a worse prognosis than BC in older patients [1, 6,[8][9][10]. According to Anders et al [11] the aggressive behavior of these tumors reflects the high frequency of triple-negative and HER-2 molecular subtypes in YA-BC. However , other studies proposed that breast cancer in young patients seems to be biologically distinct from that diagnosed in older patients, irrespective of BC distribution subtypes [12, 13]. "
    [Show abstract] [Hide abstract] ABSTRACT: Objective: Using integrated expression analyses of miRs, their mRNA and protein targets and stromal gene expression, we aimed to identify differentially expressed profiles between tumors from YA-BC and MA-BC. Methodology and results: Samples of ER+ invasive ductal breast carcinomas, divided into two groups: YA-BC (35 years or less) or MA-BC (50-65 years) were evaluated. Screening for BRCA1/2 status according to the BOADICEA program indicated low risk of patients being carriers of these mutations. Aggressive characteristics were more evident in YA-BC versus MA-BC. Performing qPCR, we identified eight miRs differentially expressed (miR-9, 18b, 33b, 106a, 106b, 210, 518a-3p and miR-372) between YA-BC and MA-BC tumors with high confidence statement, which were associated with aggressive clinicopathological characteristics. The expression profiles by microarray identified 602 predicted target genes associated to proliferation, cell cycle and development biological functions. Performing RPPA, 24 target proteins differed between both groups and 21 were interconnected within a network protein-protein interactions associated with proliferation, development and metabolism pathways over represented in YA-BC. Combination of eight mRNA targets or the combination of eight target proteins defined indicators able to classify individual samples into YA-BC or MA-BC groups. Fibroblast-enriched stroma expression profile analysis resulted in 308 stromal genes differentially expressed between YA-BC and MA-BC. Conclusion: We defined a set of differentially expressed miRNAs, their mRNAs and protein targets and stromal genes that distinguish early onset from late onset ER positive breast cancers which may be involved with tumor aggressiveness of YA-BC.
    Full-text · Article · May 2016 · PLoS ONE
  • Source
    • "A number of genes were identified with different expression between breast cancers in younger and older women. A subsequent update reported that after adjusting for clinical variables, there were no gene expression differences between the previously defined age groups [11]. To our knowledge, the effect of aging on molecular changes in breast cancer has never been comprehensively examined in multiple omic datasets (gene expression, methylation, somatic mutation, copy number variation (CNV) data, etc.). "
    [Show abstract] [Hide abstract] ABSTRACT: Breast cancer in premenopausal women (preM) is frequently associated with worse prognosis compared to that in postmenopausal women (postM), and there is evidence that preM estrogen receptor-positive (ER+) tumors may respond poorly to endocrine therapy. There is, however, a paucity of studies characterizing molecular alterations in premenopausal tumors, a potential avenue for personalizing therapy for this group of women. Using TCGA and METABRIC databases, we analyzed gene expression, copy number, methylation, somatic mutation, and reverse-phase protein array data in breast cancers from >2,500 preM and postM women. PreM tumors showed unique gene expression compared to postM tumors, however, this difference was limited to ER+ tumors. ER+ preM tumors showed unique DNA methylation, copy number and somatic mutations. Integrative pathway analysis revealed that preM tumors had elevated integrin/laminin and EGFR signaling, with enrichment for upstream TGFβ-regulation. Finally, preM tumors showed three different gene expression clusters with significantly different outcomes. Together these data suggest that ER+ preM tumors have distinct molecular characteristics compared to ER+ postM tumors, particularly with respect to integrin/laminin and EGFR signaling, which may represent therapeutic targets in this subgroup of breast cancers.
    Full-text · Article · Dec 2015 · Breast cancer research: BCR
Show more